A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

NCT01441388 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business/Operational issues

Conditions

Carcinoma, Renal Cell
Glioblastoma
Carcinoma, Hepatocellular

Interventions

DRUG: Crizotinib plus VEGF inhibitor combinations
DRUG: Crizotinib plus axitinib
DRUG: Crizotinib plus sunitinib
DRUG: Crizotinib plus axitinib
DRUG: Crizotinib plus sunitinib
DRUG: Crizotinib plus bevacizumab
DRUG: Crizotinib plus sorafenib

Sponsor

Pfizer